The global oral proteolytic enzyme market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of gastrointestinal disorders and bone diseases, which are major drivers for the growth of this market.
The global oral proteolytic enzyme market is segmented on the basis of type, application and region. On the basis of type, it is segmented into linaclotide, plecanatide, calcitonin, insulin and octreotide. On the basis of application it is segmented into gastric & digestive disorders (GDD), bone diseases (BD) and diabetes (D). On the basis of region it includes North America (NA), Latin America (LA), Europe (EU), Asia Pacific & Middle East & Africa(APMEA).
- The global Oral Proteins and Peptides market is expected to grow at a CAGR of 5.5% during the forecast period, 2018-2025.
- Increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases is driving the growth of the global Oral Proteins and Peptides market.
- Increasing awareness about oral health among people is also driving the growth of the global Oral Proteins and Peptides market.
- The increasing demand for oral care products such as toothpaste, mouthwash, chewing gum etc, are also driving the growth of the global Oral Proteins and Peptides market.
- The increasing demand for protein supplements in sports nutrition products is also driving the growth of this market.
Industry Growth Insights published a new data on “Oral Proteins and Peptides Market”. The research report is titled “Oral Proteins and Peptides Market research by Types (Linaclotide, Plecanatide, Calcitonin, Insulin, Octreotide), By Applications (Gastric & Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders), By Players/Companies Allergan, AstraZeneca, Biocon, Generex Biotechnology, Novo Nordisk, Synergy Pharmaceuticals, Tarsa Therapeutics, Sanofi, Hoffmann-La Roche, Synthetic Biologics, Hovione, Novartis”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Proteins and Peptides Market Research Report
By Type
Linaclotide, Plecanatide, Calcitonin, Insulin, Octreotide
By Application
Gastric & Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders
By Companies
Allergan, AstraZeneca, Biocon, Generex Biotechnology, Novo Nordisk, Synergy Pharmaceuticals, Tarsa Therapeutics, Sanofi, Hoffmann-La Roche, Synthetic Biologics, Hovione, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Oral Proteins and Peptides Market Report Segments:
The global Oral Proteins and Peptides market is segmented on the basis of:
Types
Linaclotide, Plecanatide, Calcitonin, Insulin, Octreotide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gastric & Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- AstraZeneca
- Biocon
- Generex Biotechnology
- Novo Nordisk
- Synergy Pharmaceuticals
- Tarsa Therapeutics
- Sanofi
- Hoffmann-La Roche
- Synthetic Biologics
- Hovione
- Novartis
Highlights of The Oral Proteins and Peptides Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Linaclotide
- Plecanatide
- Calcitonin
- Insulin
- Octreotide
- By Application:
- Gastric & Digestive Disorders
- Bone Diseases
- Diabetes
- Hormonal Disorders
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Proteins and Peptides Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral proteins and peptides are proteins and peptides that are ingested through the mouth. They can be found in many foods, such as milk, yogurt, cheese, meats, eggs and vegetables.
Some of the major players in the oral proteins and peptides market are Allergan, AstraZeneca, Biocon, Generex Biotechnology, Novo Nordisk, Synergy Pharmaceuticals, Tarsa Therapeutics, Sanofi, Hoffmann-La Roche, Synthetic Biologics, Hovione, Novartis.
The oral proteins and peptides market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oral Proteins and Peptides Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oral Proteins and Peptides Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oral Proteins and Peptides Market - Supply Chain
4.5. Global Oral Proteins and Peptides Market Forecast
4.5.1. Oral Proteins and Peptides Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oral Proteins and Peptides Market Size (000 Units) and Y-o-Y Growth
4.5.3. Oral Proteins and Peptides Market Absolute $ Opportunity
5. Global Oral Proteins and Peptides Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Oral Proteins and Peptides Market Size and Volume Forecast by Type
5.3.1. Linaclotide
5.3.2. Plecanatide
5.3.3. Calcitonin
5.3.4. Insulin
5.3.5. Octreotide
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Oral Proteins and Peptides Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Oral Proteins and Peptides Market Size and Volume Forecast by Application
6.3.1. Gastric & Digestive Disorders
6.3.2. Bone Diseases
6.3.3. Diabetes
6.3.4. Hormonal Disorders
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Oral Proteins and Peptides Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Oral Proteins and Peptides Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Oral Proteins and Peptides Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Oral Proteins and Peptides Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Oral Proteins and Peptides Demand Share Forecast, 2019-2026
9. North America Oral Proteins and Peptides Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Oral Proteins and Peptides Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Oral Proteins and Peptides Market Size and Volume Forecast by Application
9.4.1. Gastric & Digestive Disorders
9.4.2. Bone Diseases
9.4.3. Diabetes
9.4.4. Hormonal Disorders
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Oral Proteins and Peptides Market Size and Volume Forecast by Type
9.7.1. Linaclotide
9.7.2. Plecanatide
9.7.3. Calcitonin
9.7.4. Insulin
9.7.5. Octreotide
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Oral Proteins and Peptides Demand Share Forecast, 2019-2026
10. Latin America Oral Proteins and Peptides Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Oral Proteins and Peptides Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Oral Proteins and Peptides Market Size and Volume Forecast by Application
10.4.1. Gastric & Digestive Disorders
10.4.2. Bone Diseases
10.4.3. Diabetes
10.4.4. Hormonal Disorders
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Oral Proteins and Peptides Market Size and Volume Forecast by Type
10.7.1. Linaclotide
10.7.2. Plecanatide
10.7.3. Calcitonin
10.7.4. Insulin
10.7.5. Octreotide
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Oral Proteins and Peptides Demand Share Forecast, 2019-2026
11. Europe Oral Proteins and Peptides Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Oral Proteins and Peptides Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Oral Proteins and Peptides Market Size and Volume Forecast by Application
11.4.1. Gastric & Digestive Disorders
11.4.2. Bone Diseases
11.4.3. Diabetes
11.4.4. Hormonal Disorders
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Oral Proteins and Peptides Market Size and Volume Forecast by Type
11.7.1. Linaclotide
11.7.2. Plecanatide
11.7.3. Calcitonin
11.7.4. Insulin
11.7.5. Octreotide
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Oral Proteins and Peptides Demand Share, 2019-2026
12. Asia Pacific Oral Proteins and Peptides Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Oral Proteins and Peptides Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Oral Proteins and Peptides Market Size and Volume Forecast by Application
12.4.1. Gastric & Digestive Disorders
12.4.2. Bone Diseases
12.4.3. Diabetes
12.4.4. Hormonal Disorders
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Oral Proteins and Peptides Market Size and Volume Forecast by Type
12.7.1. Linaclotide
12.7.2. Plecanatide
12.7.3. Calcitonin
12.7.4. Insulin
12.7.5. Octreotide
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Oral Proteins and Peptides Demand Share, 2019-2026
13. Middle East & Africa Oral Proteins and Peptides Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Oral Proteins and Peptides Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Oral Proteins and Peptides Market Size and Volume Forecast by Application
13.4.1. Gastric & Digestive Disorders
13.4.2. Bone Diseases
13.4.3. Diabetes
13.4.4. Hormonal Disorders
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Oral Proteins and Peptides Market Size and Volume Forecast by Type
13.7.1. Linaclotide
13.7.2. Plecanatide
13.7.3. Calcitonin
13.7.4. Insulin
13.7.5. Octreotide
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Oral Proteins and Peptides Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Oral Proteins and Peptides Market: Market Share Analysis
14.2. Oral Proteins and Peptides Distributors and Customers
14.3. Oral Proteins and Peptides Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Biocon
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Generex Biotechnology
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novo Nordisk
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Synergy Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Tarsa Therapeutics
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sanofi
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Hoffmann-La Roche
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Synthetic Biologics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hovione
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Novartis
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
